TICK-BORNE ENCEPHALITIS VIRUS (TBEV), IS THE DISEASE STILL DANGEROUS?

Karolina Rogulska; https://orcid.org/0000-0003-1413-7430;karolina.rogulska@pum.edu.pl; Pomeranian Medical University, Department of Microbiology, Immunology and Laboratory Medicine, Powstańców Wielkopolskich Street 72, 70-111, Szczecin.

Patrycja Kapczuk; https://orcid.org/0000-0002-2766-7783;patrycja.kapczuk@pum.edu.pl; Pomeranian Medical University, Department of Biochemistry and Medical Chemistry; Powstańców Wielkopolskich Street 72, 70-111, Szczecin.

Anna Ziolo; annazioilo-77@wp.pl; Department of Laboratory Medicine, Immunology and HLA Laboratory, The Independent Public Clinical Hospital No. 2 of the Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich Street 72, 70-111, Szczecin.

Angela Sarna; angi420@interia.pl; Department of Laboratory Medicine, The Independent Public Clinical Hospital No. 2 of the Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich Street 72, 70-111, Szczecin.

Roksana Jacek; roksana@szachy.szczecin.pl; Department of Laboratory Medicine, The Independent Public Clinical Hospital No. 2 of the Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich Street 72, 70-111, Szczecin.

Konrad Grzeszczak; https://orcid.org/0000-0002-3055-3357; konrad.grzeszczak@pum.edu.pl; Pomeranian Medical University, Department of Biology and Medical Parasitology; Powstańców Wielkopolskich Street 72, 70-111, Szczecin.

ABSTRACT

Tick-borne encephalitis virus (TBEV) belongs to the family Flaviviridae. Flaviviruses are 50 nm viruses having a membrane envelope with an RNA genome. The vector of TBEV is the common tick (Ixodes ricinus) prevalent mainly in Europe. Tick-borne encephalitis is endemic in 27 countries in Europe. According to the National Institute of Hygiene, there are several hundred cases per year in Poland. Diagnosis of TBEV may be based on serological tests,
molecular tests, cerebrospinal fluid examination. Prevention of tick-borne encephalitis is based on several aspects and the most important are the non-compulsory vaccinations. TBEV is a disease characterised by the risk of many complications, which can be irreversible. Fortunately, thanks to developments in vaccinology, vaccinations are available to prevent infection or reduce the severity of the disease.

Keywords: tick-borne encephalitis virus; *Ixodes ricinus*; vaccinology

INTRODUCTION

Tick-borne encephalitis virus (TBEV) belongs to the family Flaviviridae. Flaviviruses are 50 nm viruses having a membrane envelope with an RNA genome. (Heinz and Allison 2003). The vector of TBEV is the common tick (*Ixodes ricinus*) prevalent mainly in Europe (Gritsun et al. 2003). The tick-borne encephalitis virus is transmitted during a tick bite via saliva. Even rapid removal of the parasite does not protect against infection, because the virus is transmitted just minutes after contact (Alekseev and Chunikhin 1990).

Tick-borne encephalitis is endemic in 27 countries in Europe (Riccardi et al. 2019). According to the National Institute of Hygiene, there are several hundred cases per year in Poland. The number of infections varies depending on the region of the country. In the course of this disease, the number of hospitalisations is extremely high - at almost 100% (Table 1).

Table 1. Tick-borne encephalitis in Poland 2017-2021 based on data from The National Institute of Public Health.

| Poland | Number of cases per quarter | Number of cases per year | Incidence per 100,000 inhabitants | Hospitalization |
|--------|-----------------------------|--------------------------|-----------------------------------|-----------------|
|        | I  | II | III | IV |                         |                  | Number | %     |
| 2017   | 8  | 33 | 101 | 141| 283                       | 0.74             | 283    | 100   |
| 2018   | 12 | 31 | 83  | 71 | 197                       | 0.51             | 197    | 100   |
| 2019   | 21 | 41 | 104 | 99 | 265                       | 0.69             | 265    | 100   |
| 2020   | 12 | 22 | 98  | 26 | 158                       | 0.41             | 158    | 100   |
| 2021   | 8  | 27 | 128 | 47 | 210                       | 0.55             | 207    | 98.6  |

Tick-borne encephalitis develops in a few days after the tick bite. The average time is eight days (Kaiser 1999). The disease usually follows a two-stage course. The first stage is asymptomatic in a significant number of people. In others, flu-like symptoms may appear, such as fever, muscle pain, fatigue and general malaise (Mickiene et al. 2002). Laboratory tests show leukopenia and thrombocytopenia (Furlan and Strle 1995). The next phase of the disease is characterised by neurological symptoms such as headache, ataxia,
tremor or spinal nerve palsy (Duniewicz et al. 1975). The severity of the disease varies from mild meningitis to encephalitis that can progress with or without myelitis (Lorenzl et al. 1996). A tick-borne encephalitis infection is associated with the risk of numerous complications including paralysis and paresis, so that is why quick and targeted diagnosis of the disease is so important.

**DIAGNOSTICS**

**Serological tests**
The diagnosis of tick-borne encephalitis is based on the detection of IgM- and IgG-class antibodies in blood or cerebrospinal fluid (CSF) using an immunoenzymatic test, e.g. ELISA (Holzmann 2003). These tests show high sensitivity, but may have lower specificity between viruses of the family of *Flaviviridae* (Weissbach and Hirsch 2015). In the course of the disease with neurological symptoms, antibodies of both classes are usually present, although sometimes only IgM antibodies are present. In this case, the tests should be repeated after about two weeks, since the recommendation is that antibodies of both IgM and IgG classes are necessary for a diagnosis of tick-borne encephalitis (Bogovic and Strle 2015). Due to the limitations of the ELISA test, a neutralisation test is recommended for people who may come into contact with flaviviruses (Taba et al. 2017). On the other hand, those who have developed infection despite vaccination should be shown to have antibodies in the PMR (Kaiser 1999).

**Molecular tests**
Polymerase chain reaction-PCR for the diagnosis of TEBV is only useful in the first phase of the disease, before seroconversion and neurological symptoms develop. (Patel et al. 2013). In the second phase of tick-borne encephalitis, PCR has no diagnostic value (Achazi et al. 2011).

**Cerebrospinal fluid examination**
In patients with suspected tick-borne encephalitis, a lumbar puncture can be performed (Deisenhammer et al. 2006). CSF mononuclear pleocytosis > 5×10⁶ cells/l is a diagnostic marker for TBEV, with the presence of IgM and IgG class antibodies in serum and a characteristic clinical presentation (Steiner et al. 2010).

**PREVENTION**
Prevention of tick-borne encephalitis is based on several aspects. First and foremost, it is important to prevent tick bites. For this purpose, light-coloured and tight clothing should be used in high-risk areas. In addition, it is advisable to use repellents which are intended to deter ticks. After returning from endemic areas, the whole body should be examined. If a tick is found, the parasite should be removed as soon as possible (Lindquist and Vapalahti 2008).

Non-mandatory vaccination against tick-borne encephalitis is also available. According to World Health Organization (WHO) In areas where the infection rate exceeds 5 cases/100,000 persons/year, population-based vaccination is indicated.

**SUMMARY**
Ticks are the most common vector of tick-borne encephalitis, so always do a self-examination when returning, i.e. from the forest. TBEV is a disease characterised by the risk of many complications, which can be irreversible. Fortunately, thanks to developments in vaccinology, vaccinations are available to prevent infection or reduce the severity of the disease.
REFERENCES

1. Achazi, K., Nitsche, A., Patel, P., Radonić, A., Mantke, O. D., & Niedrig, M. (2011). Detection and differentiation of tick-borne encephalitis virus subtypes by a reverse transcription quantitative real-time PCR and pyrosequencing. *Journal of Virological Methods*, 171(1), 34–39. https://doi.org/10.1016/J.JVIROMET.2010.09.026

2. Alekseev, A. N., & Chunikhin, S. P. (1990). Peredacha virusa kleschevogo entsefalita iksodovymi kleschami v eksperimente (mekhanizmy, sroki, vidovye i polovye razlichiaja). *Parazitologija*, 24(3), 177–185.

3. Bogovic, P., & Strle, F. (2015). Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. *World Journal of Clinical Cases: WJCC*, 3(5), 430. https://doi.org/10.12998/WJCC.V3.I5.430

4. Deisenhammer, F., Bartos, A., Egg, R., Gilhus, N. E., Giovannoni, G., Rauer, S., & Sellebjerg, F. (2006). Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. *European Journal of Neurology*, 13(9), 913–922. https://doi.org/10.1111/J.1468-1331.2006.01493.X

5. Duniewicz, M., Mertenová, J., Duniewicz, M., Jelinková, E., Holý, M., Doutlik, S., & Kulková, H. (1975). Mitteleuropäische Zeckenencephalitis in den Jahren 1969-1972 im Kreis Mittelböhmen. *Infection*, 3(4), 223–228. https://doi.org/10.1007/BF01642770

6. Gritsun, T. S., Nuttall, P. A., & Gould, E. A. (2003). Tick-Borne Flaviviruses. *Advances in Virus Research*, 61, 317–371. https://doi.org/10.1016/S0065-3527(03)61008-0

7. Heinz, F. X., & Allison, S. L. (2003). Flavivirus Structure and Membrane Fusion. *Advances in Virus Research*, 59, 63–97. https://doi.org/10.1016/S0065-3527(03)59003-0

8. Holzmann, H. (2003). Diagnosis of tick-borne encephalitis. *Vaccine*, 21(SUPPL. 1), S36–S40. https://doi.org/10.1016/S0264-410X(02)00819-8

9. Kaiser, R. (1999). The clinical and epidemiological profile of tick-borne encephalitis in southern Germany 1994-98. A prospective study of 656 patients. *Brain*, 122(11), 2067–2078. https://doi.org/10.1093/BRAIN/122.11.2067

10. Lindquist, L., & Vapalahti, O. (2008). Tick-borne encephalitis. *The Lancet*, 371(9627), 1861–1871. https://doi.org/10.1016/S0140-6736(08)60800-4

11. Lorenzl, S., Pfister, H. W., Padovan, C., & Yousry, T. (1996). MRI abnormalities in tickborne encephalitis [22]. *Lancet*, 347(9002), 698–699. https://doi.org/10.1016/S0140-6736(96)91256-8

12. Lotrič-Furlan, S., & Strle, F. (1995). Thrombocytopenia — A common finding in the initial phase of tick-borne encephalitis. *Infection 1995* 23:4, 23(4), 203–206. https://doi.org/10.1007/BF01781197

13. Mickienė, A., Laisškonis, A., Guńther, G., Vene, S., Lundkvist, Å., & Lindquist, L. (2002). Tickborne encephalitis in an area of high endemicity in lithuania: Disease severity and long-term prognosis. *Clinical Infectious Diseases*, 35(6), 650–658. https://doi.org/10.1086/342059

14. Patel, P., Landt, O., Kaiser, M., Faye, O., Koppe, T., Lass, U., … Niedrig, M. (2013). Development of one-step quantitative reverse transcription PCR for the rapid detection of flaviviruses. *Virology Journal*, 10(1), 1–11. https://doi.org/10.1186/1743-422X-10-58/TABLES/5

15. Riccardi, N., Antonello, R. M., Luzzati, R., Zajkowska, J., Di Bella, S., & Giacobbe, D. R. (2019). Tick-borne encephalitis in Europe: a brief update on epidemiology, diagnosis, prevention, and treatment. *European Journal of Internal Medicine*, 62, 1–6.
16. Steiner, I., Budka, H., Chaudhuri, A., Koskiniemi, M., Sainio, K., Salonen, O., & Kennedy, P. G. E. (2010). Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. European Journal of Neurology, 17(8), 999-e57. https://doi.org/10.1111/J.1468-1331.2010.02970.X

17. Taba, P., Schmutzhard, E., Forsberg, P., Lutsar, I., Ljøstad, U., Mygland, … Steiner, I. (2017). EAN consensus review on prevention, diagnosis and management of tick-borne encephalitis. European Journal of Neurology, 24(10), 1214-e61. https://doi.org/10.1111/ENE.13356

18. Weissbach, F. H., & Hirsch, H. H. (2015). Comparison of two commercial tick-borne encephalitis virus IgG enzyme-linked immunosorbent assays. Clinical and Vaccine Immunology, 22(7), 754–760. https://doi.org/10.1128/CVI.00096-15/SUPPL_FILE/ZCD999095213SO1.PDF